J.P. Morgan Notebook Day 1: Tax Reform At Last, Allergan's Job Cuts, Teva Turnaround, Biogen's Cash, And Getting FDA-Friendly
Executive Summary
Daily round-up of news and notes from the 2018 J.P. Morgan Healthcare Conference in San Francisco: US corporate tax reform becomes a reality, Allergan's Saunders defends patent moves as a means of protecting jobs, clarity on generic prices from Teva, Biogen's money to burn, and making the most of FDA flexibility.
You may also be interested in...
Generic Drug Sector Struggles Even As The Need For Cheaper Drugs Grows
Lower prices for generic drugs in the US are continuing to drag on revenues of drug makers like Teva, Sandoz, Mylan and Endo. Industry leaders say the US market is stabilizing, but price erosion and other negative factors impacted second quarter financials across the sector. Teva is attempting a turnaround and Mylan is exploring strategic alternatives.
Generic Drug Sector Struggles Even As The Need For Cheaper Drugs Grows
Lower prices for generic drugs in the US are continuing to drag on revenues of drug makers like Teva, Sandoz, Mylan and Endo. Industry leaders say the US market is stabilizing, but price erosion and other negative factors impacted second quarter financials across the sector. Teva is attempting a turnaround and Mylan is exploring strategic alternatives.
Biogen's SMA Ambitions Run Up Against A New Deep-Pocketed Rival
Novartis' decision to buy gene therapy developer AveXis will have a crossover impact on Biogen, an early leader in the treatment market for spinal muscular atrophy (SMA) with Spinraza.